Condition: Rare Malignant Neoplasm · Sponsor: Oslo University Hospital
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
This description comes directly from the study's public registry record.
Åslaug Helland, MD PhD · +4795940863 · ahelland@medisin.uio.no
Kathinka Slørdahl, MD PhD · katslo@ous-hf.no
Always discuss trial participation with your own doctor first.
| Oslo University Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06119789